Charles Schwab Investment Management Inc. Boosts Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Charles Schwab Investment Management Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 191,867 shares of the medical research company’s stock after buying an additional 7,552 shares during the period. Charles Schwab Investment Management Inc. owned 0.69% of Bio-Rad Laboratories worth $63,030,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Metis Global Partners LLC increased its stake in shares of Bio-Rad Laboratories by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock valued at $234,000 after buying an additional 30 shares during the period. Avior Wealth Management LLC increased its stake in shares of Bio-Rad Laboratories by 3.3% during the third quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock valued at $334,000 after buying an additional 32 shares during the period. UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the period. Finally, CIBC Asset Management Inc grew its stake in Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock worth $234,000 after purchasing an additional 34 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $251.53 on Thursday. The company has a market capitalization of $7.05 billion, a price-to-earnings ratio of -3.87 and a beta of 0.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a one year low of $244.19 and a one year high of $387.99. The company’s 50-day moving average is $315.10 and its 200 day moving average is $328.93.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BIO shares. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.